Lirimilast

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lirimilast (BAY 19-8004;BAY 198004) 是一种有效的选择性 PDE4 抑制剂，用于治疗 COPD。

Lirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.COPD Phase 2 Discontinued.

In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL.

Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation.

BAY 19-8004 | BAY 198004

Angiogenesis

PDE

PDE

Inflammation/Immunology

COPD

329306-27-6

443.251

C17H12Cl2N2O6S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (225.60 mM)

CS(=O)(OC1=CC=C2C(NC(N)=O)=C(C(C3=CC=C(Cl)C=C3Cl)=O)OC2=C1)=O

[3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate

(-20℃)

With Ice Pack

≥ 2 years